SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurex Corporation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Giuseppe Scalamogna who wrote (393)1/14/1998 7:54:00 PM
From: John McCarthy  Read Replies (1) of 449
 
Giuseppe -

I understand your relief in the fact that Morgan upgraded.

I "feel" the same relief.

Now having agreed with you, a word of caution.

The only one that gets to vote on this puppy is the ODAC and
FDA. And for this reason, Morgan's concurrence with our
opionions/hopes/aspirations etc. is nice - but has no bearing
on what will happen in those meeting(s).

And please don't under-estimate or mis-perceive Dr. John's
comment about "intent to treat" vs "evaluable".

NI has made the comment - my words not his - that hey on balance
things are okay because of the large sample size.

Well - this is a misnomer to the extent that if they threw out
40% of a large sample size, that is of profound consequence.

(Note: This was *not* the meaning NI was trying to convey, but
I am embellishing this "evaluable" point so you *hear* me
because the last time I ignored evaluabe patients - I paid dearly
for my ignorance.)

Regards,

John McCarthy
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News